DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01965496

CompletedPhase 1

A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 14 Weeks Injection of Polyethylene Glycol Loxenatide

Asset

Loxenatide / PEG-loxenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

64

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI 19-35•HbA1c 7.5-11%

Primary endpoint

•HbA1C levels after 14 weeks continuous treatment

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01965496
Org study IDPEX168-I-05

Timeline

Milestones

Study first posted2013-10-18estimated
Last update posted2013-10-18estimated
Study start2012-03 (month precision)
Primary completion2013-03actual (month precision)
Study completion2013-04actual (month precision)

Assets

Investigational agents

Loxenatide / PEG-loxenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Has been diagnosed with type 2 diabetes mellitus

2. Has been treated with either: diet and exercise alone, or with a stable regimen of one or combination of two oral antihyperglycaemic agents (except TZDs), for a minimum of 3 months prior to study start.

3. Has HbA1c of 7.5% to 11.0%, inclusive.

4. Is 20 to 72 years old, inclusive.

5. Has a body mass index (BMI) of 19 kg/m2 to 35 kg/m2, inclusive.

Exclusion criteria

1. Skin test of PEX168 is positive.

2. Is currently treated with any of the following excluded medications:

–GLP-1 or GLP-1 analogues prior to study start;
–Insulin within 6 months prior to study start;
–Growth hormone within 6 months prior to study start;
–Abuse of drug or alcohol within 6 months prior to study start;
–Any clinical trials of drugs or medical instruments within 3 months prior to study start;
–Systemic corticosteroids by oral, parenteral, or intra-articular route
–Any drugs for weight loss or operations leading to weight instable within 2 months prior to study start;
–Any drugs that may interfere the evaluation of safety and efficiency of investigated drugs, drugs or herbals medicine that may result in toxicity to main organs prior to study start;

3. A history or evidence of any of the following :

–Severe hypoglycemia history (e.g., sleepiness, consciousness disorder, deliration, coma led by hypoglycemia )
–Type 1diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes (e.g., Cushing's syndrome or acromegaly-associated diabetes).
–Other endocrine diseases (e.g., hyperthyreosis, hypothyroidism)
–Acute or chronic gastrointestinal diseases that were not suitable for the trials evaluated by investigators.
–Hypertension with SBP>140mmHg, and/or DBP >90mmHg after antihypertensive therapy.
–Severe cardiovascular diseases histories including congestive heart failure (NYHA III or IV), unstable angina, stroke or TIA, myocardial infarction,sustained and clinically relevant ventricular arrhythmia, coronary artery bypass surgery or percutaneous coronary intervention.
–Acute or chronic pancreatitis history, or pancreas injury history, or any high risk factors which may result in pancreatitis.
–Malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, regardless of whether there is evidence of local recurrence or metastases.
–Medullary thyroid carcinoma history, or multiple endocrine neoplasia history.
–Acute metabolic complications such as ketoacidosis, lactic acidosis, or hyperosmolar state (coma) , or maculopathy , or instability of proliferative retinopathy within the past 6 months.
–Weight change is over 10% within 3 months prior to the study start.
–hepatitis B positive, hepatitis C antibody positive, HIV antibody positive, syphilis antibody positive.

4. Any of the following significant laboratory abnormalities:

–Alanine aminotrasferase (ALT) and/or asparatate aminotransferase (AST)>2*upper limit of normal (ULN), and/or total bilirubin>1.5*ULN, confirmed by repeat measure;
–Creatinine > upper limit of normal, confirmed by repeat measure, and/or proteinurea>++ and 24 hour urinary protein quantitative ≥1g.
–Thyroid dysfunction unsuitable for this trial evaluated by investigator;
–Hemodlastase > upper limit of normal, confirmed by repeat measure;

5. Male or female fertility are reluctant to take contraceptive method during the test, pregnancy or lactating women;

6. Any other situations which may result in the withdrawal of subjects or bring significant risk to subjects.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Weight & body composition
1
Safety / tolerability / PK
1

Weight & body composition

1 endpoint
Other/protocol endpoint

To assess the body weights after the treatment

Time frame:14 weeks

descriptive

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

To assess HbA1C levels after 14 weeks continuous treatment

Time frame:14 weeks

descriptive

Secondary/protocol endpoint

To assess Fasting blood glucose levels

Time frame:14 weeks

descriptive

Safety / tolerability / PK

1 endpoint
Other/protocol endpoint

To assess number of participants with Adverse Events as a Measure of Safety and Tolerability

Time frame:14 weeks

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.